Viral Vector & Plasmid DNA Manufacturing Market Analysis Report By Application, By Disease (Cancer, Genetic), By Workflow (Upstream, Downstream), By Vector, By End Use, And Segment Forecasts, 2019 - 2025
The global viral vector & plasmid DNA manufacturing market size is expected to reach USD 882.9 million by 2025, according to a new report by Grand View Research, Inc., rising at a 16.0% CAGR during the forecast period. Rising number of gene therapy-based discovery programs in the pharma industry is one of the key trends driving the production of gene therapy vectors. Moreover, a robust pipeline of viral vaccines and gene therapies has prompted companies to develop novel and effective technologies for scalable manufacturing of vectors. Current vector manufacturing process is considered highly regulated, elaborate, and expensive.
Moreover, at present, there is a shortage of production sites to meet the demand by the pharmaceutical industry for vector construction services. These factors have created opportunities for companies to capitalize on potential avenues in the market through developing novel solutions.
Key growth strategies adopted by companies to sustain their market presence include continuous expansion of manufacturing sites in high-demand markets such as the U.S. and U.K. Moreover, companies are engaged in strategic mergers & facility acquisitions to meet growing requirements of viral vectors within the pharmaceutical and biotech industries and to broaden their service portfolios.
Further Key Findings From the Report Suggest: • Adenovirus and retrovirus were prominent vector type segments in the market in 2017. These can be produced at high titers and induce a strong humoral and, especially, a strong T cell response, as a result of which these vector type is extensively employed in vaccines • Lentiviral production costs nearly up to 40.0% of the total cost of goods, thus inducing revenue growth in this vector type • Downstream processing accounted for the largest share in 2017, owing to requirement of expensive equipment and skilled personnel for product recovery • In terms of application, vector manufacturing for antisense, RNAi, & molecular therapy production represented the leading revenue share in 2017. This is due to high adoption rate of viruses for oligonucleotide and aptamers development in comparison to other applications • The number of biotech companies that are engaged in employing vector for therapeutic production continue to increase over the period • Recent approval of cancer gene therapy products encourages further efforts in this arena, thus resulting in the cancer segment holding the dominant revenue share • North America led the global market owing to presence of several universities and research institutes that are engaged in genomic research programs • Cobra Biologics, Merck, uniQure N.V., and Novasep are some key participants that are focusing towards capitalizing of untapped avenues in the market.
Our reports have been used by over 10K customers, including:
411 pages •
By Global Industry Analysts
• Oct 2020
In a Major Setback to the Healthcare System, Non-COVID-19 Care Delivery Bears the Brunt of the Pandemic. Gene Therapy Market Slumps by -13.6% The global market for Gene Therapy is expected to decline by -13.6% in the year 2020 and thereafter recover and grow to reach US$3.3 billion by the year 2027, trailing a post COVID-19 CAGR of...
Hepatocyte Growth Factor - Pipeline Review, H2 2020 Summary According to the recently published report ’Hepatocyte Growth Factor - Pipeline Review, H2 2020’; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules. Hepatocyte Growth...
Neuropeptide Y Receptor Type 2 - Pipeline Review, H2 2020 Summary Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules. The latest report Neuropeptide Y Receptor Type 2 - Pipeline Review, H2 2020, outlays comprehensive information on the Neuropeptide...
300 pages •
By The Business Research Company
• Nov 2020
Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global gene therapy market market. This report focuses on gene therapy market market which is experiencing strong growth. The report gives a guide to the...
The cell and gene therapy segment is one of the fastest growing segments in the biopharmaceutical space.While the science behind the therapy has grown by leaps and bounds on the back of decades worth of research, manufacturing has unfortunately lagged behind. To fully harness the curative potential of these therapies and ensure greater...